Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Radiation and Chemotherapy in High Intermediate Risk Endometrial Cancer
NCT03932409Phase 1Active, not recruiting
- Sponsor
- University of Oklahoma
- Start
- Feb 2020
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in endometrial cancer (EC), sponsored by University of Oklahoma. Primary endpoint: Proportion of patients completing three cycles at 4 months. Started Feb 2020; status: active, not recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03932409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03932409.